Show simple item record

dc.creatorButini, Stefania
dc.creatorNikolić, Katarina
dc.creatorKassel, S.
dc.creatorBrueckmann, H.
dc.creatorFilipić, Slavica
dc.creatorAgbaba, Danica
dc.creatorGemma, S.
dc.creatorBrogi, S.
dc.creatorBrindisi, M.
dc.creatorCampiani, G.
dc.creatorStark, Holger
dc.date.accessioned2019-09-02T11:55:47Z
dc.date.available2019-09-02T11:55:47Z
dc.date.issued2016
dc.identifier.issn0301-0082
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/2738
dc.description.abstractMost neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson's disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.en
dc.publisherPergamon-Elsevier Science Ltd, Oxford
dc.relationEU COST Action CA 15135
dc.relationEU COST Action CM 1103
dc.relationEU COST Action CM 1207
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172033/RS//
dc.relationDFG - INST2018/664-1
dc.rightsrestrictedAccess
dc.sourceProgress in Neurobiology
dc.titlePolypharmacology of dopamine receptor ligandsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractКассел, С.; Филипић, Славица; Бруецкманн, Х.; Гемма, С.; Бриндиси, М.; Цампиани, Г.; Николић, Катарина; Бутини, Стефаниа; Старк, Холгер; Броги, С.; Aгбаба, Даница;
dc.citation.volume142
dc.citation.spage68
dc.citation.epage103
dc.citation.other142: 68-103
dc.citation.rankaM21
dc.identifier.wos000379093100004
dc.identifier.doi10.1016/j.pneurobio.2016.03.011
dc.identifier.pmid27234980
dc.identifier.scopus2-s2.0-84973527131
dc.identifier.rcubconv_3607
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record